Loading…
Onesource Specialty Pharma (ONESOURCE)₹1,618−0.89%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Onesource Specialty Pharma reported sales of ₹517 Cr, up 37.2% from Sep 2025, and net profit of ₹57.15 Cr, up 469.8% year on year. For the year to Mar 2026, sales were ₹1,423 Cr and net profit −₹74.21 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56.01 | 73.12 | 292 | 334 | 394 | 426 | 327 | 377 | 290 | 428 | 450 | 517 |
| Expenses | 67.23 | 76.23 | 229 | 258 | 252 | 244 | 240 | 270 | 274 | 337 | 327 | 354 |
| Operating Profit | −10.02 | −3.01 | 64.12 | 77.16 | 142 | 183 | 88.24 | 106 | 17.04 | 92.28 | 123 | 163 |
| OPM % | −19.1% | −3.8% | 22.0% | 23.0% | 36.0% | 42.9% | 27.0% | 28.0% | 6.0% | 20.9% | 26.9% | 32.0% |
| Other Income | −73.74 | 2.99 | −0.99 | −0.99 | −93.73 | 1.99 | 1.99 | 2.99 | −1.99 | 1.99 | 0.00 | −0.99 |
| Interest | 26.07 | 20.07 | 42.13 | 45.20 | 46.14 | 33.12 | 27.08 | 34.13 | 38.12 | 23.08 | 31.13 | 35.14 |
| Depreciation | 19.97 | 19.95 | 67.83 | 67.85 | 68.86 | 67.91 | 67.92 | 69.91 | 69.92 | 71.91 | 71.82 | 74.90 |
| Profit before tax | −130 | −39.90 | −46.87 | −36.89 | −66.80 | 82.82 | −3.99 | 5.98 | −92.72 | 0.00 | 19.93 | 52.85 |
| Tax % | 0.0% | 0.0% | −88.1% | 11.9% | 4.0% | −19.1% | −96.1% | −83.1% | −5.0% | −1,630.1% | −23.1% | −9.0% |
| Exceptional items | −74.86 | 0.00 | −3.99 | −3.99 | −94.88 | −0.99 | −2.99 | 0.00 | −6.99 | 0.00 | −3.99 | −1.99 |
| Net Profit | −130 | −40.08 | −6.02 | −42.10 | −69.15 | 98.18 | 0.00 | 10.03 | −89.27 | 5.01 | 25.04 | 57.15 |
| EPS (Rs) | — | — | — | — | −6.01 | 8.60 | −0.01 | 0.91 | −7.72 | 0.39 | 2.17 | 5.00 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 21.03 | 132 | 39.04 | 172 | 1,447 | 1,423 | 1,685 |
| Expenses | 93.36 | 230 | 200 | 255 | 981 | 1,121 | 1,292 |
| Operating Profit | −71.19 | −97.26 | −161 | −82.19 | 468 | 305 | 396 |
| OPM % | −334.1% | −73.1% | −415.1% | −48.1% | 31.9% | 20.9% | 23.5% |
| Other Income | 0.99 | 3.99 | −524 | −143 | −93.66 | 4.98 | −0.99 |
| Interest | 16.06 | 68.21 | 48.21 | 89.33 | 167 | 122 | 127 |
| Depreciation | 33.96 | 69.90 | 65.87 | 75.82 | 274 | 279 | 289 |
| Profit before tax | −121 | −230 | −798 | −390 | −67.86 | −91.77 | −19.94 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | −73.1% | −20.1% | — |
| Exceptional items | 0.00 | 1.99 | −144 | −122 | −98.77 | −9.98 | −12.97 |
| Net Profit | −121 | −231 | −802 | −392 | −18.03 | −74.21 | −2.07 |
| EPS (Rs) | — | — | — | — | −1.56 | −6.43 | −0.16 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2.01 | 3.01 | 4.01 | 4.01 | 11.03 | 11.03 |
| Reserves | 773 | 1,007 | 779 | 391 | 5,875 | 5,824 |
| Borrowings | 388 | 1,158 | 867 | 564 | 775 | 1,282 |
| Other Liabilities | 96.46 | 276 | 366 | 467 | 1,010 | 1,203 |
| Total Liabilities | 1,259 | 2,443 | 2,017 | 1,427 | 7,671 | 8,320 |
| Fixed Assets | 635 | 1,236 | 1,364 | 866 | 6,138 | 6,041 |
| CWIP | 430 | 489 | 333 | 187 | 218 | 528 |
| Investments | 0.00 | 0.00 | 3.99 | 19.98 | 15.97 | 15.98 |
| Other Assets | 194 | 720 | 313 | 355 | 1,300 | 1,735 |
| Inventories | 4.99 | 275 | 139 | 128 | 265 | 533 |
| Trade receivables | 2.01 | 24.09 | 4.01 | 55.15 | 418 | 693 |
| Cash & equivalents | 78.03 | 170 | 79.99 | 60.03 | 301 | 98.11 |
| Total Assets | 1,259 | 2,443 | 2,017 | 1,427 | 7,671 | 8,320 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | −118 | −415 | −163 | −107 | −67.80 | 8.97 |
| Cash from investing activity | −207 | −691 | −67.89 | 510 | −201 | −494 |
| Cash from financing activity | 382 | 1,163 | 118 | −391 | 412 | 360 |
| Net cash flow | 56.22 | 54.22 | −112 | 13.06 | 144 | −127 |
| Capex | 208 | 657 | 44.11 | 64.15 | 128 | 571 |
| Free cash flow | −324 | −1,068 | −206 | −170 | −195 | −560 |
| CFO / OP % | 164.0% | 430.0% | 107.9% | 130.0% | −13.0% | 6.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory days | 86 | 1,804 | 614 | 257 | 221 | 437 |
| Days payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash conversion cycle | −637 | 1,461 | 232 | 212 | 180 | 308 |
| Working capital days | −2,392 | −1,291 | −6,745 | −877 | −58 | −6 |
| ROCE % | — | −10.0% | −12.0% | −12.0% | 6.0% | 1.0% |
For the Sep 2026 quarter, Onesource Specialty Pharma reported sales of ₹517 Cr, up 37.2% year on year and net profit of ₹57.15 Cr, up 469.8% year on year. The operating margin was 32.0%.
Onesource Specialty Pharma's sales for the year to Mar 2026 were ₹1,423 Cr; over the last twelve months they were ₹1,685 Cr.
Net profit for the year to Mar 2026 was −₹74.21 Cr, and −₹2.07 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−0.16.
Onesource Specialty Pharma reported borrowings of ₹1,282 Cr at Mar 2026, against cash and equivalents of ₹98.11 Cr.
Cash from operations was ₹8.97 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹560 Cr.